1. My Clinical Approach to PI-RADS
At my urology practice in Rhodes, one of the most common questions I hear is: “Doctor, what does the PI-RADS score on my MRI report actually mean?” It's completely understandable — patients see a number from 1 to 5 and immediately worry it means cancer.
My role is not simply to read out the score, but to place it within your overall clinical picture — PSA, PSA density, age, family history, digital rectal examination findings — so that together we can reach an individualised, well-informed decision.
In practice, I always follow these principles:
- Interpret the PI-RADS score together with PSA and PSA density, never in isolation.
- Clearly explain to the patient that PI-RADS is not a cancer diagnosis.
- Individualise the decision for biopsy, particularly for PI-RADS 3 findings.
- Recommend targeted (fusion) biopsy when there is a clear imaging indication.
The aim of this guide is to help you understand what your MRI result actually means — clearly, and without unnecessary worry.
2. What Is PI-RADS
PI-RADS stands for Prostate Imaging Reporting and Data System. It is a standardised assessment system for multiparametric prostate MRI (mpMRI), currently in version v2.1, jointly developed by the American College of Radiology (ACR) and the European Society of Urogenital Radiology (ESUR).
Before PI-RADS, different radiologists described the same findings using different terminology, making communication with the urologist difficult. Standardised reporting solves this problem: every suspicious lesion is scored using the same criteria, regardless of the centre or radiologist performing the assessment.
Which mpMRI sequences are assessed
- T2-weighted imaging (T2W) — depicts prostate anatomy in high detail.
- Diffusion-weighted imaging / ADC (DWI) — assesses the cellular density of the lesion, a key scoring factor.
- Dynamic contrast enhancement (DCE) — used as a supplementary sequence, mainly for equivocal peripheral zone findings.
Important: PI-RADS does not express the likelihood of any prostate cancer, but specifically the likelihood of clinically significant prostate cancer (csPCa) — disease that, if confirmed, would most likely require some form of treatment or close monitoring.
3. PI-RADS Scores 1–5 Explained
PI-RADS 1 — Very Low Likelihood
The presence of clinically significant cancer is considered very unlikely.
PI-RADS 2 — Low Likelihood
The presence of clinically significant cancer is considered unlikely.
PI-RADS 3 — Intermediate / Equivocal Likelihood
The finding is equivocal. The decision for biopsy depends significantly on PSA density, PSA, age, family history, digital rectal examination, prior biopsy, lesion size/characteristics, and overall individual risk.
PI-RADS 4 — High Likelihood
There is a significant likelihood of clinically significant cancer. Further urological evaluation and consideration of targeted biopsy are usually required.
PI-RADS 5 — Very High Likelihood
The finding is highly suspicious for clinically significant cancer. A PI-RADS 5 score does not equal a histological cancer diagnosis — the definitive diagnosis is made by biopsy, when indicated.
4. PI-RADS Table: Interpretation & Approach
| PI-RADS | Interpretation | Usual Next Step |
|---|---|---|
| 1 | Very low suspicion | Clinical correlation |
| 2 | Low suspicion | Clinical correlation |
| 3 | Equivocal finding | Risk stratification / PSA density |
| 4 | High suspicion | Often an indication for biopsy |
| 5 | Very high suspicion | Strong indication for further work-up |
The “Usual next step” column is not an absolute treatment rule. The final decision is always individualised, based on each patient's complete clinical profile.
5. PI-RADS 3: The Equivocal Finding
PI-RADS 3 is often the most confusing score for patients, because it does not give a clear-cut answer. It does not mean a “normal MRI”, but it does not mean “cancer” either — it is literally an intermediate, equivocal finding.
The decision for biopsy in PI-RADS 3 depends on:
PSA density
Total PSA
Age
Family history
Digital rectal examination
Prior biopsy
Lesion size & characteristics
Overall individual risk
For this reason, PSA density plays a particularly important role when assessing a PI-RADS 3 finding — see below for details.
6. What Is PSA Density
PSA density is calculated as:
PSA density = PSA Ă· Prostate Volume
It is particularly useful when MRI shows a PI-RADS 3 finding, because it helps distinguish whether an elevated PSA simply reflects a large prostate, or a genuinely higher risk.
In clinical practice, an indicative threshold of around 0.15 ng/mL/cc is often used. This is not an absolute, non-negotiable cutoff — modern, risk-adapted approaches may use different thresholds depending on the MRI appearance and the patient's overall risk profile.
The decision for biopsy should never be based on PSA density alone — it is one of several factors in the overall clinical assessment.
7. PI-RADS & PSA: The Overall Picture
PI-RADS is never interpreted in isolation. The following are always taken into account:
- Total PSA
- PSA density
- PSA change over time, where clinically relevant
- Age
- Prostate volume
- Digital rectal examination
- Family history
- Prior negative biopsy
- Prior MRI scans
PSA change over time (“PSA velocity”) may have clinical value in selected cases, but should not be used as a standalone decision criterion — it is always considered as part of the complete clinical picture.
8. When Is a Biopsy Needed & What Is Fusion Biopsy
The need for biopsy is determined by a combination of: PI-RADS score, PSA density, total PSA, clinical examination, age, family history, prior findings, and any previous negative biopsy.
MRI-Targeted / Fusion Prostate Biopsy
For suspicious lesions, the preferred technique is often an MRI-targeted (fusion) biopsy. The MRI images are “fused” with real-time ultrasound, so the needle can be guided precisely to the exact location of the suspicious (PI-RADS) lesion — rather than relying on “blind” sampling from random areas of the gland.
Depending on the clinical case, targeted biopsy may be combined with systematic cores from across the gland, in line with current guidelines, to maximise the sensitivity of detecting clinically significant disease.
9. The Diagnostic Pathway, Step by Step
Treatment is not decided based on the PI-RADS score. It is decided only after histological diagnosis, based on the Gleason score / ISUP Grade Group, PSA, clinical stage, age, comorbidities, life expectancy and patient preferences. See the “From Diagnosis to Treatment” section below.
10. Common Patient Concerns
Does PI-RADS 5 definitely mean cancer?
No. It means a very high imaging suspicion, not a histological diagnosis. Rarely, benign or inflammatory changes can have an appearance that mimics a suspicious lesion. The definitive diagnosis is made by biopsy, when indicated.
Can a PI-RADS 2 result still hide cancer?
No imaging method has 100% sensitivity. A low PI-RADS score significantly reduces the likelihood of clinically significant cancer, but does not eliminate it — which is why MRI is always interpreted together with the overall clinical risk.
What happens after a negative biopsy?
In cases of a negative biopsy combined with persistent clinical suspicion, elevated PSA density, a PI-RADS 4–5 lesion, or a change on MRI, further follow-up or re-evaluation may be needed — without a fixed, universal timeline.
Is a follow-up MRI always needed?
Repeat MRI may be used in selected cases — particularly during active surveillance, for a PI-RADS 3 finding, after a prior negative biopsy, or when the PSA/risk profile changes. There is no universal “MRI every X months” recommendation — frequency is individualised.
11. From Diagnosis to Treatment
PI-RADS is neither a staging system nor a treatment system. It is an imaging assessment tool that guides the decision for biopsy.
The logic of the modern diagnostic pathway is: MRI → PI-RADS → possible biopsy → histological diagnosis → Gleason score / ISUP Grade Group → staging → choice of treatment.
Treatment of prostate cancer is decided only after the diagnosis is confirmed, and depends on the Gleason score / ISUP Grade Group, PSA, clinical stage, age, comorbidities, life expectancy and the patient's preferences.
Possible treatment approaches (depending on stage)
- Active surveillance for low-risk disease.
- Robotic or 3D laparoscopic radical prostatectomy for localised disease.
- Radiotherapy, in selected stages.
- Systemic therapies, in appropriately advanced stages.
12. Frequently Asked Questions
What does PI-RADS mean on a prostate MRI?
PI-RADS (Prostate Imaging Reporting and Data System) is a standardised 1–5 scoring system used on multiparametric MRI (mpMRI) of the prostate to estimate the likelihood of clinically significant prostate cancer. It is not a diagnosis in itself — it is a tool that guides further work-up.
What does a PI-RADS 3 score mean?
It means an equivocal, intermediate finding — neither reassuring nor clearly suspicious. Whether a biopsy is needed depends on additional factors, particularly PSA density, as well as age, family history and digital rectal examination findings.
Does PI-RADS 4 mean cancer?
Not automatically. PI-RADS 4 indicates a high imaging likelihood of clinically significant cancer and usually leads to a recommendation for targeted biopsy, but a definitive diagnosis can only be made by histological examination.
Does PI-RADS 5 mean I definitely have prostate cancer?
No. It means a very high imaging suspicion, not a histological confirmation. Rarely, benign or inflammatory changes can mimic the appearance of a PI-RADS 5 lesion. Biopsy remains necessary for a definitive diagnosis.
When is a biopsy needed after a prostate MRI?
The need for biopsy is not determined by the PI-RADS score alone, but by a combination of factors: PI-RADS score, PSA, PSA density, age, family history and prior biopsies. In PI-RADS 4–5, the indication is usually strong; in PI-RADS 3, the decision is individualised.
What is PSA density?
It is PSA divided by prostate volume. It helps determine whether an elevated PSA simply reflects a large prostate or reflects a genuinely higher risk, and is used particularly when assessing a PI-RADS 3 finding.
Can a PI-RADS 2 result still hide cancer?
No imaging test has 100% sensitivity. A low PI-RADS score significantly reduces, but does not eliminate, the likelihood of clinically significant cancer — which is why MRI is always interpreted together with the patient's overall clinical risk.
What is a prostate fusion biopsy?
It is a targeted biopsy that combines MRI images with real-time ultrasound, so the needle can be guided precisely to the suspicious (PI-RADS) lesion, usually together with systematic samples from across the gland.
What happens if the biopsy is negative but the PI-RADS score remains high?
In cases of persistent clinical suspicion, elevated PSA density, a PI-RADS 4–5 lesion, or a change on imaging, further follow-up, re-evaluation or repeat biopsy may be needed — always individualised, not on a fixed timetable.
Can the PI-RADS score change on a follow-up MRI?
Yes. PI-RADS reflects the appearance on that specific scan. On a repeat MRI, the score may stay the same, increase, or decrease, depending on how the finding evolves and the technical quality of the imaging.
Related Topics
Have an MRI Result with PI-RADS 3, 4 or 5?
Correct interpretation requires assessing the MRI together with your PSA, PSA density and overall clinical profile. Book an appointment for a personalised urological evaluation and, where indicated, planning of a targeted (fusion) biopsy at our practice in Rhodes.
Scientific References
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer 2026 — uroweb.org
- American College of Radiology (ACR) & European Society of Urogenital Radiology (ESUR) — Prostate Imaging Reporting and Data System (PI-RADS) v2.1 — acr.org
- European Society of Urogenital Radiology (ESUR) — esur.org
- Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update. Eur Urol 2019.
Meet the Physician
Dr. Marinos Vasilas
Surgical Urologist – Andrologist
Dr. Marinos Vasilas applies an mpMRI-first diagnostic approach at his practice in Rhodes, using PI-RADS scoring and targeted (fusion) biopsy where indicated, in line with the guidelines of the European Association of Urology (EAU).
Meet the Doctor